On Monday, Viridian Therapeutics Inc (NASDAQ: VRDN) was -1.64% drop from the session before settling in for the closing price of $24.98. A 52-week range for VRDN has been $10.93 – $25.39.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
A company in the Healthcare sector has dropped its sales by -12.71% annually for the last half of the decade. When this article was written, the company’s average yearly earnings per share was at 27.08%. With a float of $68.00 million, this company’s outstanding shares have now reached $76.36 million.
In an organization with 96 employees, it is important to assess its efficiency. In terms of profitability, gross margin is -2268.4%, operating margin of -87078.47%, and the pretax margin is -79185.76%.
Viridian Therapeutics Inc (VRDN) Insider Updates
Also, it is sometimes useful to examine the sentiment of large-scale investors toward Viridian Therapeutics Inc stocks. The insider ownership of Viridian Therapeutics Inc is 10.95%, while institutional ownership is 81.93%. The most recent insider transaction that took place on Sep 27 ’24, was worth 117,050. In this transaction Chief Operating Officer of this company bought 5,000 shares at a rate of $23.41, taking the stock ownership to the 6,000 shares. Before that another transaction happened on Sep 27 ’24, when Company’s President and CEO bought 21,400 for $23.33, making the entire transaction worth $499,262. This insider now owns 21,400 shares in total.
Viridian Therapeutics Inc (VRDN) Performance Highlights and Predictions
Going through the last 3-months fiscal report unveiled on the 6/30/2024, it has been observed that the corporation posted -1.09 earnings per share (EPS) during the time that was better than consensus figure (set at -1.27) by 0.18. Wall Street market experts anticipate that the next fiscal year will bring earnings of -1.03 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around 27.08% per share during the next fiscal year.
Viridian Therapeutics Inc (NASDAQ: VRDN) Trading Performance Indicators
You can see what Viridian Therapeutics Inc (VRDN) is doing with its current performance indicators. In the most recent quarter, the stock posted a quick ratio of 15.82. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 6469.54.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -4.25, a number that is poised to hit -1.06 in the next quarter and is forecasted to reach -4.18 in one year’s time.
Technical Analysis of Viridian Therapeutics Inc (VRDN)
Let’s dig in a bit further. During the last 5-days, its volume was 0.84 million. That was inferior than the volume of 1.12 million it reported in year-ago period. As of the previous 9 days, the stock’s Stochastic %D was 86.83%. Additionally, its Average True Range was 1.32.
During the past 100 days, Viridian Therapeutics Inc’s (VRDN) raw stochastic average was set at 94.17%, which indicates a significant increase from 78.97% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 44.00% in the past 14 days, which was lower than the 71.96% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $19.53, while its 200-day Moving Average is $16.95. However, in the short run, Viridian Therapeutics Inc’s stock first resistance to watch stands at $25.22. Second resistance stands at $25.86. The third major resistance level sits at $26.45. If the price goes on to break the first support level at $23.98, it is likely to go to the next support level at $23.40. Assuming the price breaks the second support level, the third support level stands at $22.75.
Viridian Therapeutics Inc (NASDAQ: VRDN) Key Stats
There are 63,822K outstanding shares of the company, which has a market capitalization of 1.88 billion. As of now, sales total 310 K while income totals -237,730 K. Its latest quarter income was 70 K while its last quarter net income were -64,990 K.
